Development of Repositioned Drug Molecules for Inflammatory Skin Diseases

Introduction

The product is a novel topical formulation of existing oral anti-parasitic drug/s which are repositioned for treatment of inflammatory skin diseases like Psoriasis. This product has evolved from repurposing of existing oral anti-parasitic drugs. Being repurposed product, significant safety information is already available for the drugs, mainly requiring efficacy to be established for the new indication.

 

Stage of Development

 

Proof of Concept.

 

Unique Features of The Product/Technology

 

This product is topical formulation for treatment of inflammatory skin diseases and has evolved from repurposing of existing oral anti-parasitic drugs. Being repurposed product, significant safety information is already available for the drugs, mainly requiring efficacy to be established for the new indication. This product being repositioned drug will have lower development costs and hence will be affordable. Most of the topical treatments become ineffective over time & no new topical drug has been approved by USFDA in last 10 years for psoriasis.

 

Market Potential

 

Drugs to treat psoriasis is expected to grow to a value of USD 3,834.5 million by 2018, at a compound annual growth rate CAGR of 8.2 percent. Existing topical drugs are steroids, Vitamin D analogues, Anthralin, Retinoid, calcineurin inhibitors, Salicylic acid and Coal Tar.

 

National/Societal Relevance

 

According to Indian psoriasis foundation around 5 percent of India`s population is affected by psoriasis.

 

For further information please contact

 

Biotechnology Industry Research Assistance Council (BIRAC)

1 st Floor, MTNL Building, 9, CGO Complex,

Lodhi Road, New Delhi- 110003

Phone: + 91-11-24389600

Email- birac.dbt@nic.in